Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic

Abstract

BackgroundTherapeutic failure with antiretroviral therapy (ART) is a substantial issue where viral rebound, viral resistance and drug-related toxicity remain serious concerns. Drug exposure-response relationships have been described for the protease inhibitors, pharmacokinetic variability is substantial for this class of drugs and drug interactions can also alter ART exposure. Given this background we established a therapeutic drug monitoring (TDM) service to monitor atazanavir (ATV) plasma concentrations early after the therapy was made available to treatment-experienced people infected with HIV who were managed in a clinical setting. MethodsThis was a prospective observational study which evaluated plasma samples from 110 highly treatment-experienced people with HIV using TDM and applied pharmacokinetic analysis over a five month period. ResultsATV trough concentrations exhibited substantial intersubject variability ( < 25-2108 m g l -1 ). A substantial number of subjects (50%,13/26) who received ATV400 mg daily had low exposure to ATV. Serum bilirubin concentrations correlated significantly with higher ATV trough concentrations ( r = 0.803; P < 0.001) and 55% (29/53) of subjects who received ATV300/100 mg RTV daily had plasma concentrations above a proposed target concentration associated with elevated bilirubin concentrations. This study confirmed low ATV exposure in eight subjects with HIV receiving ATV 400 mg daily. Reasons for low ATV exposure in this cohort include administration of interacting drugs, including a possible interaction with ritonavir, fluticasone and ATV, impaired ATV absorption secondary to suspected achlorhydria and potential interactions with colchicine and nandrolone. Viral load remained undetectable in most of these subjects with low ATV exposure. ConclusionsTDM and targeted pharmacokinetic studies should be viewed as fundamental tools in the development and clinical application of ART, to improve pharmacotherapy for people with HIV.J. E. Ray et al. 29260 :3 Br J Clin Pharmacol

The Use of Betaine HCl to Enhance Dasatinib Absorption in Healthy Volunteers with Rabeprazole-Induced Hypochlorhydria

“…Previously, oral acidic solutions (i.e., cola beverages) have been used in an attempt to raise the extent of drug absorption following the administration of a weakly basic drug with an ARA (4,14,15). However, data from these studies suggest that this strategy may be inconsistent for various weakly basic drugs, as cola was unable to consistently reverse the reduced absorption caused by the ARA.…”

Population Pharmacokinetics of Atazanavir in Patients with Human Immunodeficiency Virus Infection

“…Therefore, new strategies based on target concentration dosage adaptation have gained increasing importance for better management of HIV-infected patients (20), and therapeutic drug monitoring (TDM) with Bayesian dosage adaptation has been proposed as a way to individualize therapy according to plasma ATV concentration. This approach must be based on accurate knowledge of the drug's average pharmacokinetic profile and variability.…”

Influence of Nevirapine on Gastrointestinal Function

“…Increased intestinal motility and transit may be due to a seemingly irritable bowel. NVP may therefore not be beneficial in diarrheal states since it may provoke or aggravate diarrhea [44]. …”